BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation
ClinicalTrials.gov ID: NCT06218420
What this study is testing
- What it's testing
- The aim of this trial is to carry out the first prospective multicentric study which evaluates the efficacy and the safety of SBRT in HCC patients enlisted for LT and not suitable for other bridging interventional treatments (RF or TACE). The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and is currently the first indication for Liver transplantation (LT).
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- Patients enlisted for LT in France for HCC or undergoing pre-transplant assessment (under Agence de Biomédecine (ABM) regulation)
- HCC previously treated or naive
- Suitable for stereotactic radiotherapy:
- ECOG, performance status score ≤ 2,
You likely can't join if
- Inability to comply with study procedures
- Patients under guardianship or curatorship
- Pregnancy (Positiveurinary/blood βHCG test)
See the full eligibility criteria
- Age ≥ 18 years old
- Patients enlisted for LT in France for HCC or undergoing pre-transplant assessment (under Agence de Biomédecine (ABM) regulation)
- HCC previously treated or naive
- Suitable for stereotactic radiotherapy:
- ECOG, performance status score ≤ 2,
- Child-Pugh Score ≤ B7,
- Number of lesions between 1 and 3
- Maximum tumor size \< 5cm Liver remnant volume ≥ 700 ml. The liver remnant volume will be measured at the baseline visit or M0. If the volume is \<700 ml, the patient will be in early discontinuation of the study.
- Health insurance coverage.
- Written informed consent
- Inability to comply with study procedures
- Patients under guardianship or curatorship
- Pregnancy (Positiveurinary/blood βHCG test)
The study team makes the final eligibility decision.
Where it's taking place
- Paris, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.